Germany’s BioNTech (NASDAQ: BNTX) has licensed a pre-clinical antibody candidate and additional antibody-drug conjugate (ADC) technology from Portugal-based biotechnology company CellmAbs. The agreement marks Portugal’s first billion-dollar transaction in the life sciences sector. Under the terms, CellmAbs will receive undisclosed upfront and near-term payments, potential milestone payments reaching several hundred million USD, and sales royalties.
CellmAbs, which specializes in ADCs, bispecific T-cell engagers (BiTEs), and cell therapies in oncology, will phase out its current operations. This move allows the company’s founders to pursue new ventures in oncology and longevity research.- Flcube.com
